Potassium channels: New targets in cancer therapy
Introduction
Cancer is a multifactor process that involves several temporal steps. Cells first acquire a phenotype through the altered expression of proteins and genes. Afterwards, tumour cells proliferate massively and do not undergo apoptosis. Chemotherapy and radiosensitization have been widely used to block this progression. However, the use of these therapies is not synonymous with success. Nucleoside analogues have been widely used as a first attempt to control the cell cycle. These molecules are taken up by the cells by means of membrane transport systems. Nucleoside derivatives (i.e. fludarabine or gemcitabine, among others) used in cancer and antiviral therapies interfere with nucleoside metabolism and DNA replication, thus inducing their pharmacological effects [1]. In fact, nucleoside uptake is induced during proliferation. The inhibition of nucleoside transport systems by nucleoside derivatives arrests the cell cycle in the S phase [2], [3], [4], [5]. Several nucleoside carriers have been described and molecularly characterized. Their activities overlap and their expression depends on the tissue and the differentiation status of the cell [5], [6].
Although a lot of effort is involved in designing individual treatments, most current strategies are not selective. They may be harmful and are sometimes unsuccessful. In some cases, this lack of efficiency could be explained by tumour cells’ extraordinary ability to develop a multidrug resistance (MDR) phenotype in response to chemotherapy [7], [8]. Thus, adaptive regulation, overlapped transport activities and their expression are the main obstacles in cancer therapeutics.
Novel technologies such as genomics and proteomics have increased the number of human genes known to be differentially expressed in normal and malignant tissues. We have entered a new era, leaving cytotoxic approaches behind to focus on mechanisms based on gene therapy and pharmacogenomics. This new perspective has produced a large body of evidence indicating that KCh could play a relevant role in cancer therapy.
Targeting potassium channels for cancer therapy could give rise to successful strategies for the following reasons:
- i)
KCh are involved in cell proliferation as they control cell cycle progression.
- ii)
KCh show cell and tissue-specific expression.
- iii)
These proteins are highly sensitive to synthetic blockers and natural peptides, leading pharmaceutical companies to design more effective and selective molecules.
- iv)
Current therapies for nerve and cardiac diseases successfully target KCh and have few side effects.
- v)
Impaired expression of KCh has been detected in a number of cancer and tumour cells.
In addition, overexpression of KCh has been described in some MDR cell lines and K+ channels effectors may partially reverse the MDR phenotype [7]. Furthermore, KCh control upstream nucleoside derivative uptake pathways [9]. Therefore, a combination of therapies involving chemotherapeutic agents and K+ channels blockers has been proposed.
Section snippets
Methods
The criteria for the data selection in this review were the evidences obtained through an electronic data base search in PubMed of literature mainly published in the last 8 years (1998–2005). In addition, approximately one-fourth of the references were from the last two years. Only relevant papers prior to these dates were also considered. The searches were limited to articles published in English. Various combinations were searched using the keywords “potassium channels”, “cancer”, “cell
Criteria for the selection of studies
Because the aim of this review is to highlight the involvement of potassium channels in cancer progression and pathology, studies were selected for citing based on their relevance to this purpose. The evidences may also suggest that these proteins can be used as tumour markers in cancer detection. In addition, the latest literature indicates that the time has come to consider potassium channels when developing new strategies for cancer therapy. The information has been summarized descriptively
Conclusions
Potassium channels in cell membranes regulate cellular excitability and proliferation. The central role of these ion channels in cell function has made them the target of several channelopathies. In light of the increasing amount of evidence showing that KCh are involved in cell proliferation and tumour growth, it seems that these proteins could be considered a pharmacological tool during cancer progression and pathology. The persistence of the MDR phenotype handicaps the treatment and the
Acknowledgements
The work carried out by the Molecular Physiology Laboratory was funded by grants from the Universitat de Barcelona, the Generalitat de Catalunya and the Ministerio de Educación y Ciencia (MEC), Spain awarded to AF. RV is the recipient of a fellowship from the Universitat de Barcelona. NV and RM hold fellowships from the MEC. MR-F is a research fellow of the Generalitat de Catalunya. The editorial assistance of the Language Advisory Service from the University of Barcelona is also acknowledged.
References (124)
- et al.
Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies
Trends Pharmacol Sci
(1998) - et al.
Modulation of Kv channel alpha/beta subunit interactions
Trends Cardiovasc Med
(1999) K(+) channels as therapeutic drug targets
Pharmacol Ther
(2002)- et al.
Differential voltage-dependent K+ channel responses during proliferation and activation in macrophages
J Biol Chem
(2003) - et al.
hSK4/hIK1, a calmodulin-binding KCa channel in human T lymphocytes. Roles in proliferation and volume regulation
J Biol Chem
(1999) - et al.
Ion channels in the immune system as targets for immunosuppression
Curr Opin Biotechnol
(1997) - et al.
Cell-cycle- dependent expression of the large Ca2+-activated K+ channels in breast cancer cells
Biochem Biophys Res Commun
(2004) - et al.
Effects of intermediate-conductance Ca2+-activated K+ channel modulators on human prostate cancer cell proliferation
Eur J Pharmacol
(2003) - et al.
Molecular and pharmacological properties of inwardly rectifying K+ channels of human lung cancer cells
Eur J Pharmacol
(2002) - et al.
Developmental expression of voltage-sensitive K+ channels in mouse skeletal muscle and C2C12 cells
FEBS Lett
(1992)
Possible involvement of aquaporin-7 and -8 in rat testis development and spermatogenesis
Biochem Biophys Res Commun
Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene
Cancer Cell
Cytokine-cytokine interactions and the brain
Brain Res Bull
The systemic inflammatory response is involved in the regulation of K(+) channel expression in brain via TNF-alpha-dependent and -independent pathways
FEBS Lett
Impaired voltage-gated K+ channel expression in brain during experimental cancer cachexia
FEBS Lett
Histopathology of liver cancers
Best Pract Res Clin Gastroenterol
Information dynamics in carcinogenesis and tumor growth
Mutat Res
Targeted point mutagenesis of mouse Kcnq1: phenotypic analysis of mice with point mutations that cause Romano-Ward syndrome in humans
Genomics
KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness
Cell
A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome
Cell
The long QT syndromes: genetic basis and clinical implications
J Am Coll Cardiol
KCNE1-like gene is deleted in AMME contiguous gene syndrome: identification and characterization of the human and mouse homologs
Genomics
KV1.1 K(+) channels identification in human breast carcinoma cells: involvement in cell proliferation
Biochem Biophys Res Commun
Expression and activity of potassium ion channels in human prostate cancer
Cancer Lett
Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells
J Biol Chem
Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells
J Biol Chem
Inward rectifying potassium channels in human malignant glioma cells
Brain Res
Kir 4.1 channel expression in neuroblastomaxglioma hybrid NG108-15 cell line
Brain Res Dev Brain Res
Differential expression and regulation of nucleoside transport systems in rat liver parenchymal and hepatoma cells
Hepatology
Macrophages require different nucleoside transport systems for proliferation and activation
FASEB J
Na+-dependent nucleoside transport in liver: two different isoforms from the same gene family are expressed in liver cells
Biochem J
Nucleoside transporters and liver cell growth
Biochem Cell Biol
The concentrative nucleoside transporter family (SLC28): new roles beyond salvage?
Biochem Soc Trans
Targeting K+ channels for cancer therapy
J Exp Ther Oncol
Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells
J Natl Cancer Inst
ATP-sensitive K(+) channels regulate the concentrative adenosine transporter CNT2 following activation by A(1) adenosine receptors
Mol Cell Biol
Ion channels of excitable membranes
Potassium channels, proliferation and G1 progression
J Membr Biol
Voltage-gated potassium channels in cell proliferation
Physiology (Bethesda)
Voltage-gated K+ channels in human T lymphocytes: a role in mitogenesis?
Nature
Pattern of Kv beta subunit expression in macrophages depends upon proliferation and the mode of activation
J Immunol
Effect of K+ channel blockers on anti-immunoglobulin-induced murine B cell proliferation
J Clin Lab Immunol
Hypoxia regulates expression and activity of Kv1.3 channels in T lymphocytes: a possible role in T cell proliferation
J Immunol
Shaker-type potassium channel subunits differentially control oligodendrocyte progenitor proliferation
Glia
Inhibition of tumor cell proliferation by sigma ligands is associated with K+ Channel inhibition and p27kip1 accumulation
J Pharmacol Exp Ther
Voltage-activated K+ channels and membrane depolarization regulate accumulation of the cyclin-dependent kinase inhibitors p27(Kip1) and p21(CIP1) in glial progenitor cells
J Neurosci
Roles of K+ channels in regulating tumour cell proliferation and apoptosis
Pflugers Arch
Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo
J Immunol
T cell activation is regulated by voltage-dependent and calcium-activated potassium channels
J Immunol
Blockage of intermediate-conductance Ca2+-activated K+ channels inhibit human pancreatic cancer cell growth in vitro
Mol Pharmacol
Cited by (114)
Therapeutic effects of guanidine hydrochloride on breast cancer through targeting KCNG1 gene
2023, Biomedicine and PharmacotherapyThe distinguishing electrical properties of cancer cells
2022, Physics of Life ReviewsStatins as inhibitors of voltage-gated potassium channels Kv1.3 in cancer cells
2021, Journal of Molecular Structure